

# A large-scale histological investigation gives insight into the structure of ischemic stroke thrombi

Jooss, Natalie; Poulter, Natalie

DOI:

[10.1080/09537104.2020.1869713](https://doi.org/10.1080/09537104.2020.1869713)

License:

Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)

*Document Version*

Peer reviewed version

*Citation for published version (Harvard):*

Jooss, N & Poulter, N 2021, 'A large-scale histological investigation gives insight into the structure of ischemic stroke thrombi', *Platelets*, vol. 32, no. 2, pp. 147-150. <https://doi.org/10.1080/09537104.2020.1869713>

[Link to publication on Research at Birmingham portal](#)

## **Publisher Rights Statement:**

This is an Accepted Manuscript version of the following article, accepted for publication in *Platelets*. Natalie J. Jooss & Natalie S. Poulter (2021) A large-scale histological investigation gives insight into the structure of ischemic stroke thrombi, *Platelets*, DOI: 10.1080/09537104.2020.1869713. It is deposited under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (<http://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.

## **General rights**

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

## **Take down policy**

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact [UBIRA@lists.bham.ac.uk](mailto:UBIRA@lists.bham.ac.uk) providing details and we will remove access to the work immediately and investigate.

# **A large-scale histological investigation gives insight into the structure of ischemic stroke thrombi**

Natalie J. Jooss<sup>a,b,\*</sup>, Natalie S. Poulter<sup>a,c</sup>

*<sup>a</sup> Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK.*

*<sup>b</sup> Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, 6229 ER Maastricht, The Netherlands*

*<sup>c</sup> Centre of Membrane Proteins and Receptors (COMPARE), Universities of Birmingham and Nottingham, Midlands, UK.*

*\*Corresponding author; Natalie Jooss, Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK. email: [NJJ844@bham.ac.uk](mailto:NJJ844@bham.ac.uk)*

Worldwide, 15 million people suffer a stroke every year<sup>1</sup>, it is therefore a significant global health and financial burden. In Europe alone, there were more than 600,000 people who endured a stroke in 2015 and this is estimated to increase to over 800,000 by 2035, equating to a massive financial burden of 45 billion Euros<sup>2</sup>. The majority of strokes (85%) are ischemic, triggered by a thrombus occluding a blood vessel, decreasing oxygen supply to the affected area and resulting in tissue damage. The remaining 15% of strokes are hemorrhagic and caused by rupture of a major vessel<sup>3,4</sup>. The severity of stroke can vary; in Europe it is the second most common cause of death<sup>5</sup> but even if the patient recovers, rehabilitation can take many months, or even years, and some individuals have to learn to live with permanent disabilities as a result of the stroke<sup>2</sup>. The best outcome for the patient is achieved if the blood flow is restored as promptly as possible<sup>6</sup>. European guidelines indicate that treatment for ischemic stroke should occur within the first 4.5 h of the onset of symptoms<sup>3</sup>. At present there are two approved treatment strategies for stroke. Most patients are treated with intravenous administration of recombinant tissue plasminogen activator (rtPA)<sup>2</sup>, an enzyme that catalyses the conversion of plasminogen to plasmin, which induces thrombolysis (clot breakdown)<sup>3</sup>. A more recently employed technique is thrombectomy, where the clot is retrieved mechanically<sup>7,8</sup>. In many cases, these treatments are not sufficient to remove the occluding thrombus and restore blood flow. The underlying reason for this is still not fully understood. It is thought that this may be related to the great heterogeneity that is present in the stroke-causing thrombi that could make a clot more, or less, susceptible to degradation by rtPA or affect the likelihood of successful retrieval. Understanding the thrombus composition and structure could lead to more targeted and effective treatments for stroke<sup>6</sup>.

The recent work of Staessens *et al.*<sup>9</sup> has made further advances in addressing the question of thrombus composition. In this paper the authors interrogated the structure of

177 thrombi from acute ischemic stroke patients isolated by thrombectomy and have made further steps towards deciphering the cellular components involved<sup>9</sup>. To our knowledge, this is the first study to use such a large number of samples to systematically characterize thrombus structure utilizing histological stains and immunofluorescence labelling for red blood cells (RBC), platelets, fibrin(ogen), von Willebrand factor (vWF) and DNA.

In the present study<sup>9</sup> thrombi were retrieved and analyzed from ischemic stroke patients, regardless of prior rtPA treatment. However, the authors did not correlate the results with the treatment to determine if there was any effect of the rtPA on thrombus structure. Further, they also acknowledge that findings may potentially be biased, as only retrievable thrombi were interrogated. In fact, there is evidence that RBC-rich thrombi are more easily removed by thrombectomy<sup>10</sup>. Nevertheless, all 177 thrombi in this study were subjected to the full range of analyses, with authors able to show that thrombi contain RBC-rich as well as platelet-rich areas. Regardless of the above-mentioned limitations, they elegantly demonstrate the continuum observed in the makeup of thrombi and the proportion of RBC-rich and platelet-rich areas, summarized in Figure 1. Within the different zones, Staessens *et al.*<sup>9</sup> showed that RBC-rich areas were composed of densely packed RBCs with a fine fibrin meshwork throughout. Nucleated cells, vWF and platelets were rarely seen in these areas. This relatively simple structure is in contrast to the platelet-rich areas where fibrin and vWF often colocalized, and leukocytes and an abundance of extracellular DNA were observed. The extracellular DNA was hypothesized to be the result of neutrophil extracellular traps (NETs) formation which has been shown to not only interact with platelets<sup>11</sup> but also to play a role in venous thrombosis<sup>12,13</sup>. However, further staining for citrullinated histone h3<sup>14</sup> and myeloperoxidase was not performed<sup>15</sup>. More specific staining for NETosis can confirm that the detected DNA is in fact neutrophil-derived and not induced by cell death or necrosis; additionally, it also makes it

possible to narrow down the specific pathway of the neutrophil activation and subsequent NET formation<sup>16</sup>.

Putting these observations into the context of other studies the authors speculate that the rtPA resistance of platelet-rich thrombi could be due to DNA modification of the fibrin structure<sup>17,18</sup>. They also suggest that covalent cross-linking of vWF and fibrin by Factor XIII may contribute to the rtPA resistance<sup>19-23</sup>. Factor XIII is a transglutaminase which circulates in the blood as an inactive zymogen. Once activated by thrombin (to become FXIIIa), it can crosslink fibrin via isopeptide bonds which increases clot stability and makes it more resistant to fibrinolysis. FXIIIa has also been shown to crosslink vWF to fibrin<sup>21</sup>. As both fibrin and vWF have been observed to colocalise in the thrombus it would be interesting to probe the sections for Factor XIII to see if it was also present to support this hypothesis. This could explain why less than half of the patients that receive rtPA treatment to induce thrombolysis have a positive outcome<sup>24,25</sup>. The present work, therefore, strongly suggests DNase and/or ADAMTS13 (a plasma metalloproteinase that cleaves vWF) may increase thrombolysis. These interesting findings warrant more in-depth study of rtPA alone or in combination with DNase1/ADAMTS13. In fact, Denorme *et al.*<sup>26</sup> have shown the presence of vWF in 36 ischemic stroke thrombi, but also that tPA treatment was more efficient after pre-infusion of ADAMTS13 in a murine stroke model<sup>26</sup>. Very recent work by Ahmed *et al.*<sup>27</sup> has shown that the platelet collagen and fibrin(ogen) receptor GPVI might be involved in stabilizing thrombi. Hence, an anti-GPVI agent could be used in combination with rtPA to promote disaggregation of platelet-rich thrombi<sup>27</sup>. This again provides further evidence that understanding thrombus structure could offer enhanced treatment strategies. It will be interesting to see whether the results of these mouse model and in vitro studies hold true in patient studies to see if such

combination therapies could be used in the future to increase the success of stroke treatment and patient outcomes.

Although the conclusions of Staessens *et al.*<sup>9</sup> are based on a large dataset, detailed quantification of the data obtained by immunohistochemistry for vWF, platelets, fibrin(ogen) and leukocytes is missing. Quantification of the impressive number of thrombi investigated could potentially provide not only numerical data in order to compare different thrombi, but also present the opportunity to interrogate the heterogeneity within an individual thrombus. A machine-learning approach to quantify labelled thrombus sections has been used previously<sup>28,29</sup> and the work by Staessens *et al.*<sup>9</sup> would benefit from a similar approach and therefore presents an opportunity for further exploitation of their large dataset.

This study is an important addition to a whole body of work that could significantly improve outcomes for stroke patients by improving treatment strategies. Similar studies state various patient parameters such as gender, age, preexisting conditions, stroke aetiology or even occlusion site<sup>30,31</sup>. Connecting them to thrombus morphology could be key in determining patient-specific therapeutic approaches. Therefore, follow-up studies should be pursued that investigate the correlation between thrombus structure and patient parameters, as well as plasma samples, to give more information on how different factors influence stroke severity, as well as patient outcome. Boeckh-Behrens *et al.*<sup>32</sup> investigated whether the underlying cause for ischemic stroke in 145 patients was due to a cardioembolic event. By combining semi-quantitative analysis of the thrombi with clinical data they concluded that most strokes were of cardioembolic origin<sup>32</sup>. More information about thrombus structure poses the potential to expand the choice and manner of treatment strategies thereby improving outcomes for ischemic stroke patients. In fact, there is evidence that in coronary thrombi fibrin content increases, while

the presence of platelets decreases the ischemic time (duration from onset of symptoms to the primary percutaneous intervention)<sup>33</sup>.

Whilst this is a well-executed study, the conclusions are based upon observations and further experimental work is required. For example, laser capture microdissection could be utilized to not only visualize areas of interest, but also enable incorporation of other experimental measures such as proteomics, transcriptomics, or genomics to investigate regions/cells<sup>34</sup>. This type of approach would complement existing data obtained from mass spectrometry on stroke thrombi where Munoz *et al.*<sup>35</sup> identified 339 proteins commonly detected in the four patients investigated<sup>35</sup>. Further, as there is evidence that the composition of the thrombus plays an important role in the efficacy of thrombolytic treatment, it would be of interest to know what the underlying mechanism is for the formation of the two thrombi subpopulations (RBC- or platelet-rich). For example, different shear rates may influence the composition of the thrombus<sup>36</sup> and this could be something to further interrogate. Also, changes in the vessel wall, which can be picked up by noninvasive imaging techniques such as CT or MRI, have been correlated to an increased amount of RBC in the thrombus<sup>37</sup>.

In summary, the authors are in the possession of a large treasure trove of samples. Other studies conducted on comparable specimens with similar methodologies did so with far fewer samples<sup>38,39</sup> or did not carry out such in-depth investigations<sup>32</sup>. The present study elegantly offers validation for textbook knowledge in a large cohort of patients, thereby laying the foundation for more in-depth investigations to improve treatment options for ischemic stroke patients.

## Acknowledgements

NJJ is funded by a European Union's Horizon 2020 research and innovation program under Marie Skłodowska-Curie grant agreement No. 766118. NSP is supported by the British Heart Foundation through the Chair award (CH0/03/003) to Steve P. Watson. We thank Christopher W. Smith for critical reading of the manuscript.

## Conflicts of Interest

The authors declare no competing financial interests


## References

1. WHO. The Atlas of Heart Disease and Stroke, Deaths from stroke, [https://www.who.int/cardiovascular\\_diseases/en/cvd\\_atlas\\_15\\_burden\\_stroke.pdf](https://www.who.int/cardiovascular_diseases/en/cvd_atlas_15_burden_stroke.pdf). Accessed 09.11.2020.
2. Stevens E. MC, Emmett E., Wolfe C., Wang Y. The Burden Of Stroke In Europe – Challenges For Policy Makers, <https://strokeeurope.eu/media/download/StrokeAllianceforEurope2017>. Accessed 05.09.2020.
3. Mahmood SS, Levy D, Vasan RS, Wang TJ. The Framingham Heart Study and the epidemiology of cardiovascular disease: a historical perspective. *Lancet*. 2014;383(9921):999-1008.
4. Tadi P, Lui F. Acute Stroke. BTI - StatPearls.
5. Timmis A, Townsend N, Gale C, et al. European Society of Cardiology: Cardiovascular Disease Statistics 2017.39(7):508–579.
6. Vidale. S, Agostoni. EC. Organizing Healthcare for Optimal Acute Ischemic Stroke Treatment. *J Clin Neurol*. 2020;16(2):183-190.
7. Prabhakaran S, Ruff I, Bernstein RA. Acute stroke intervention: a systematic review.313(14):1451-1462.
8. Vanacker P, Lambrou D, Eskandari A, et al. Improving the Prediction of Spontaneous and Post-thrombolytic Recanalization in Ischemic Stroke Patients.24(8):1781-1786.
9. Staessens S, Denorme F, Francois O, et al. Structural analysis of ischemic stroke thrombi: histological indications for therapy resistance. *Haematologica*.2020 Jan 31;105(2):498-507.
10. Mengozzi L, Widimsky P. The potential value of histological analysis of thrombi extracted through mechanical thrombectomy during acute ischemic stroke treatment. *Anatol J Cardiol*.2020 Apr;23(5):254-259.
11. Fuchs TA, Brill A Fau - Duerschmied D, Duerschmied D Fau - Schatzberg D, et al. Extracellular DNA traps promote thrombosis.107(36):15880-15885.
12. Martinod K, Wagner DD. Thrombosis: tangled up in NETs. *Blood*. 2014;123(18):2768-2776.
13. Brill A, Fuchs TA, Savchenko AS, et al. Neutrophil extracellular traps promote deep vein thrombosis in mice. *J Thromb Haemost*. 2012;10(1):136-144.



14. Leshner M, Wang S, Lewis C, et al. PAD4 mediated histone hypercitrullination induces heterochromatin decondensation and chromatin unfolding to form neutrophil extracellular trap-like structures. *Frontiers in Immunology*. 2012-October-04 2012;3(307).
15. Brinjikji W, Duffy S, Burrows A, et al. Correlation of imaging and histopathology of thrombi in acute ischemic stroke with etiology and outcome: a systematic review. *J Neurointerv Surg*. 2017;9(6):529-534.
16. Masuda S, Nakazawa D, Shida H, et al. NETosis markers: Quest for specific, objective, and quantitative markers. (459):89-93.
17. Longstaff C, Varjú I Fau - Sótonyi P, Sótonyi P Fau - Szabó L, et al. Mechanical stability and fibrinolytic resistance of clots containing fibrin, DNA, and histones. *J Biol Chem*. 2013 Mar 8;288(10):6946-56.
18. Ryan EA, Mockros Lf Fau - Weisel JW, Weisel JW Fau - Lorand L, Lorand L. Structural origins of fibrin clot rheology. *Biophys J*. 1999 Nov;77(5):2813-26.
19. Miszta A, Pelkmans L, Lindhout T, et al. Thrombin-dependent Incorporation of von Willebrand Factor into a Fibrin Network. 289(52):35979-35986.
20. Keuren JF, Baruch D Fau - Legendre P, Legendre P Fau - Denis CV, et al. von Willebrand factor C1C2 domain is involved in platelet adhesion to polymerized fibrin at high shear rate. 103(5):1741-1746.
21. Hada M Fau - Kaminski M, Kaminski M Fau - Bockenstedt P, Bockenstedt P Fau - McDonagh J, McDonagh J. Covalent crosslinking of von Willebrand factor to fibrin. 68(1):95-101.
22. Denorme F, Langhauser F, Desender L, et al. ADAMTS13-mediated thrombolysis of t-PA-resistant occlusions in ischemic stroke in mice. 127(19):2337-2345.
23. Martinez de Lizarrondo S, Gakuba C, Herbig BA, et al. Potent Thrombolytic Effect of N-Acetylcysteine on Arterial Thrombi. 136(7):646-660.
24. Prabhakaran S, Ruff I, Bernstein RA. Acute stroke intervention: a systematic review. *JAMA*. 2015 Apr 14;313(14):1451-62.
25. Vanacker P, Lambrou D, Eskandari A, et al. Improving the Prediction of Spontaneous and Post-thrombotic Recanalization in Ischemic Stroke Patients. *J Stroke Cerebrovasc Dis*. 2015 Aug;24(8):1781-6.
26. Denorme F, Langhauser F, Desender L, et al. ADAMTS13-mediated thrombolysis of t-PA-resistant occlusions in ischemic stroke in mice. *Blood*. 2016 May 12;127(19):2337-45.
27. Ahmed MU, Kaneva V, Loyau S, et al. Pharmacological Blockade of Glycoprotein VI Promotes Thrombus Disaggregation in the Absence of Thrombin. *Arterioscler Thromb Vasc Biol*. 2020 Sep;40(9):2127-2142.
28. Douglas A, Fitzgerald S, Mereuta OM, et al. Platelet-rich emboli are associated with von Willebrand factor levels and have poorer revascularization outcomes. *J Neurointerv Surg*. 2020;12(6):557.
29. Bankhead P, Loughrey MB, Fernández JA, et al. QuPath: Open source software for digital pathology image analysis. *Sci Rep*. 2017 Dec 4;7(1):16878.
30. Maekawa K, Shibata M, Nakajima H, et al. Erythrocyte-Rich Thrombus Is Associated with Reduced Number of Maneuvers and Procedure Time in Patients with Acute Ischemic Stroke Undergoing Mechanical Thrombectomy. *Cerebrovasc Dis Extra*. 2018;8(1):39-49.
31. Riegger J, Byrne RA, Joner M, et al. Histopathological evaluation of thrombus in patients presenting with stent thrombosis. A multicenter European study: a report of the prevention of late stent thrombosis by an interdisciplinary global European effort consortium†. *European Heart Journal*. 2015;37(19):1538-1549.

32. Boeckh-Behrens T, Kleine JF, Zimmer C, et al. Thrombus Histology Suggests Cardioembolic Cause in Cryptogenic Stroke. *Stroke*.2016 Jul;47(7):1864-71.
33. Silvain J, Collet J-P, Nagaswami C, et al. Composition of coronary thrombus in acute myocardial infarction. *J Am Coll Cardiol*. 2011;57(12):1359-1367.
34. Leica. Laser Microdissection LMD, <https://www.leica-microsystems.com/solutions/life-science/laser-microdissection/>. 2020. Accessed 16.10.2020.
35. Muñoz R, Santamaría EA-O, Rubio I, et al. Mass Spectrometry-Based Proteomic Profiling of Thrombotic Material Obtained by Endovascular Thrombectomy in Patients with Ischemic Stroke. *Int J Mol Sci*.2018 Feb 7;19(2):498.
36. Mehta BP, Nogueira RG. Should clot composition affect choice of endovascular therapy? ;79(13 Suppl 1):S63-67.
37. Liebeskind DS, Sanossian N Fau - Yong WH, Yong Wh Fau - Starkman S, et al. CT and MRI early vessel signs reflect clot composition in acute stroke. *Stroke*.2011 May;42(5):1237-43.
38. Marder VJ, Chute Dj Fau - Starkman S, Starkman S Fau - Abolian AM, et al. Analysis of thrombi retrieved from cerebral arteries of patients with acute ischemic stroke. *Stroke*.2006 Aug;37(8):2086-93.
39. Niesten JM, van der Schaaf IC, van Dam L, et al. Histopathologic composition of cerebral thrombi of acute stroke patients is correlated with stroke subtype and thrombus attenuation. *PLoS One*.2014 Feb 11;9(2):e88882.



**Figure 1** – Different thrombus morphology as observed by Staessens et al.<sup>5</sup>

Thrombi from stroke patients extracted by mechanical removal (thrombectomy) were found to be composed of a platelet-rich areas containing thick fibrin fibers, seemingly crosslinked with vWF and DNA. Red blood cell (RBC)-rich areas, with a loose fibrin network and some leukocytes were also present. Interestingly, leukocytes and DNA were shown to colocalize at the border between platelet- and RBC-rich areas. The 177 thrombi analyzed showed a full range of compositions from predominantly platelet-rich to almost entirely RBC-rich. This figure was created with BioRender.com.